-
Je něco špatně v tomto záznamu ?
Hemopatch® is effective and safe to use: real-world data from a prospective European registry study
C. Lombardo, S. Lopez-Ben, U. Boggi, P. Gutowski, T. Hrbac, L. Krska, J. Marquez-Rivas, D. Russello, E. York, M. Zacharias
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie
- MeSH
- hemostatika * škodlivé účinky MeSH
- hemostáza chirurgická metody MeSH
- krvácení při operaci MeSH
- lidé MeSH
- obory chirurgické * MeSH
- prospektivní studie MeSH
- registrace MeSH
- skot MeSH
- výsledek terapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- skot MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
Surgical procedures are often impeded by bleeding and/or leakage of body fluids. These complications cannot always be resolved by conventional surgical techniques. Hemopatch® is a hemostatic patch that also functions as a sealant. Here we document the effectiveness and safety of Hemopatch® for routine procedures of multiple surgical disciplines. To this end, we performed a prospective, multicenter, single-arm, observational registry study. Patients were eligible if they had received Hemopatch® during an open or minimally invasive procedure in one of these specialties: hepatobiliary, cardiovascular, urological, neurological/spinal, general, or lung surgery. Patients were excluded if they had a known hypersensitivity to bovine proteins or brilliant blue, intraoperative pulsatile or severe bleeding and/or infection at the target application site (TAS). The primary endpoint for intraoperative effectiveness was hemostasis assessed as the percentage of patients achieving hemostasis within 2 min and the percentage of patients achieving hemostasis without re-bleeding at the time of surgical closure. The registry enrolled 621 patients at 23 study sites in six European countries. Six hundred twenty patients had completed follow-up information. Hemostasis within 2 min was achieved at 463 (74.5%) of all 621 TASs. Hemostasis without re-bleeding was observed at 620 (99.8%) TASs. Adverse events were reported in 64 patients (10.3%). This Hemopatch® registry shows that Hemopatch® efficiently establishes hemostasis and sealing in a variety of surgical specialties, including minimally invasive procedures. Furthermore, we provide evidence for the safety of Hemopatch® across all the specialties included in the registry. This study is registered at clinicaltrials.gov: NCT03392662.
Clinic for Urology Vivantes Auguste Viktoria Klinikum Berlin Germany
Clinic for Vascular Surgery Samodzielny Public Hospital Szczecin Poland
Department of Pediatric Surgery Hospital Universitario Virgen del Rocio Seville Spain
Department of Surgery Hospital La Paz Madrid Spain
Division of General and Transplant Surgery University of Pisa Pisa Italy
General Surgery Unit Azienda Ospedaliera per l'Emergenza Cannizzaro Catania Italy
Neurosurgical Clinic University Hospital Ostrava Poruba Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024331
- 003
- CZ-PrNML
- 005
- 20221031100406.0
- 007
- ta
- 008
- 221017s2022 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13304-022-01353-y $2 doi
- 035 __
- $a (PubMed)35986865
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Lombardo, Carlo $u Division of General and Transplant Surgery, University of Pisa, Pisa, Italy. carlolombardomd@gmail.com $1 https://orcid.org/http://orcid.org/0000000344111143
- 245 10
- $a Hemopatch® is effective and safe to use: real-world data from a prospective European registry study / $c C. Lombardo, S. Lopez-Ben, U. Boggi, P. Gutowski, T. Hrbac, L. Krska, J. Marquez-Rivas, D. Russello, E. York, M. Zacharias
- 520 9_
- $a Surgical procedures are often impeded by bleeding and/or leakage of body fluids. These complications cannot always be resolved by conventional surgical techniques. Hemopatch® is a hemostatic patch that also functions as a sealant. Here we document the effectiveness and safety of Hemopatch® for routine procedures of multiple surgical disciplines. To this end, we performed a prospective, multicenter, single-arm, observational registry study. Patients were eligible if they had received Hemopatch® during an open or minimally invasive procedure in one of these specialties: hepatobiliary, cardiovascular, urological, neurological/spinal, general, or lung surgery. Patients were excluded if they had a known hypersensitivity to bovine proteins or brilliant blue, intraoperative pulsatile or severe bleeding and/or infection at the target application site (TAS). The primary endpoint for intraoperative effectiveness was hemostasis assessed as the percentage of patients achieving hemostasis within 2 min and the percentage of patients achieving hemostasis without re-bleeding at the time of surgical closure. The registry enrolled 621 patients at 23 study sites in six European countries. Six hundred twenty patients had completed follow-up information. Hemostasis within 2 min was achieved at 463 (74.5%) of all 621 TASs. Hemostasis without re-bleeding was observed at 620 (99.8%) TASs. Adverse events were reported in 64 patients (10.3%). This Hemopatch® registry shows that Hemopatch® efficiently establishes hemostasis and sealing in a variety of surgical specialties, including minimally invasive procedures. Furthermore, we provide evidence for the safety of Hemopatch® across all the specialties included in the registry. This study is registered at clinicaltrials.gov: NCT03392662.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krvácení při operaci $7 D016063
- 650 _2
- $a skot $7 D002417
- 650 _2
- $a hemostáza chirurgická $x metody $7 D006488
- 650 12
- $a hemostatika $x škodlivé účinky $7 D006490
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a registrace $7 D012042
- 650 12
- $a obory chirurgické $7 D013043
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Lopez-Ben, Santiago $u Hepatobiliary and Pancreatic Surgery Unit, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain $1 https://orcid.org/http://orcid.org/0000000251929966
- 700 1_
- $a Boggi, Ugo $u Division of General and Transplant Surgery, University of Pisa, Pisa, Italy $1 https://orcid.org/http://orcid.org/0000000275055896
- 700 1_
- $a Gutowski, Piotr $u Clinic for Vascular Surgery, Samodzielny Public Hospital, Szczecin, Poland
- 700 1_
- $a Hrbac, Tomas $u Neurosurgical Clinic, University Hospital, Ostrava-Poruba, Czech Republic $1 https://orcid.org/http://orcid.org/0000000264019849
- 700 1_
- $a Krska, Lukas $u Neurosurgical Clinic, University Hospital, Ostrava-Poruba, Czech Republic
- 700 1_
- $a Marquez-Rivas, Javier $u Department of Pediatric Surgery, Hospital Universitario Virgen del Rocio, Seville, Spain $1 https://orcid.org/http://orcid.org/0000000251364723
- 700 1_
- $a Russello, Domenico $u General Surgery Unit, Azienda Ospedaliera per l'Emergenza Cannizzaro, Catania, Italy $1 https://orcid.org/http://orcid.org/0000000177574334
- 700 1_
- $a York, Elisa $u Department of Surgery, Hospital La Paz, Madrid, Spain
- 700 1_
- $a Zacharias, Mario $u Clinic for Urology, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany
- 773 0_
- $w MED00208705 $t Updates in surgery $x 2038-3312 $g Roč. 74, č. 5 (2022), s. 1521-1531
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35986865 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100403 $b ABA008
- 999 __
- $a ok $b bmc $g 1854195 $s 1175621
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 74 $c 5 $d 1521-1531 $e 20220820 $i 2038-3312 $m Updates in surgery $n Updates Surg $x MED00208705
- LZP __
- $a Pubmed-20221017